Combination of vemurafenib and cobimetinib in patients with advanced BRAFV600-mutated melanoma: a phase 1b study (vol 15, pg 954, 2014)

被引：0
|
作者：
Ribas, A.
Gonzalez, R.
Pavlick, A.
机构：
来源：
LANCET ONCOLOGY | 2014年 / 15卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E417 / E417
页数：1
相关论文
共 50 条
  • [11] A prospective observational safety study of patients with BRAFV600-mutated unresectable or metastatic melanoma treated with vemurafenib (Zelboraf Safety Study)
    Corrie, P. G.
    Terheyden, P.
    ten Tije, A. J.
    Herbst, R.
    Jansen, R.
    Marples, M.
    Debus, D.
    Marconcini, R.
    Blasinska-Morawiec, M.
    Freivogel, K.
    Munson, M. L. G.
    Goodman, G. R.
    Hsu, J. J.
    Sadetsky, N.
    Colburn, D.
    Rutkowski, P.
    [J]. BRITISH JOURNAL OF DERMATOLOGY, 2019, 180 (05) : 1254 - 1255
  • [12] Extended follow-up results of a phase 1b study (BRIM7) of cobimetinib combined with vemurafenib in BRAFV600-mutant melanoma
    Daud, A.
    Pavlick, A. C.
    Ribas, A.
    Gonzalez, R.
    Lewis, K. D.
    Hamid, O.
    Gajewski, T. F.
    Puzanov, I.
    Hsu, J. J.
    Rooney, I.
    Choong, N. W.
    Mcarthur, G. A.
    [J]. MELANOMA RESEARCH, 2016, 26 : E35 - E36
  • [13] Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma
    Blay, J. Y.
    Cropet, C.
    Mansard, S.
    Loriot, Y.
    De La Fouchardiere, C.
    Haroche, J.
    Topart, D.
    Tougeron, D.
    You, B.
    Italiano, A.
    Le Brun-Ly, V.
    Ferrero, J. M.
    Penel, N.
    Fabbro, M.
    Troussard, X.
    Malka, D.
    Ray-Coquard, I.
    Leboulleux, S.
    Flechon, A.
    Maubec, E.
    Charles, J.
    Dalle, S.
    Taieb, S.
    Garcia, G. C. T. E.
    Mandache, A. M.
    Colignon, N.
    Gavrel, M.
    Nowak, F.
    Labouret, N. Hoog
    Oukhatar, C. Mahier Ait
    Gomez-Roca, C.
    [J]. ESMO OPEN, 2023, 8 (06)
  • [14] Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation–positive melanoma
    Brigitte Dréno
    Paolo A Ascierto
    Victoria Atkinson
    Gabriella Liszkay
    Michele Maio
    Mario Mandalà
    Lev Demidov
    Daniil Stroyakovskiy
    Luc Thomas
    Luis de la Cruz-Merino
    Caroline Dutriaux
    Claus Garbe
    Karen Bartley
    Thomas Karagiannis
    Ilsung Chang
    Isabelle Rooney
    Daniel O Koralek
    James Larkin
    Grant A McArthur
    Antoni Ribas
    [J]. British Journal of Cancer, 2018, 118 : 777 - 784
  • [15] 5-Year Overall Survival in COLUMBUS: a randomized Phase 3 Study of Encorafenib plus Binimetinib versus Vemurafenib or Encorafenib in Patients with BRAFV600-mutated Melanoma
    Dummer, R.
    Flaherty, K.
    Robert, C.
    Arance, A.
    de Groot, J. W.
    Garbe, C.
    Gogas, H.
    Gutzmer, R.
    Krajsova, I.
    Liszkay, G.
    Loquai, C.
    Mandala, M.
    Schadendorf, D.
    Yamazaki, N.
    Pickard, M. D.
    Zohren, F.
    Edwards, M.
    Ascierto, P. A.
    [J]. JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 56 - 56
  • [16] Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma
    Dreno, Brigitte
    Ascierto, Paolo A.
    Atkinson, Victoria
    Liszkay, Gabriella
    Maio, Michele
    Mandala, Mario
    Demidov, Lev
    Stroyakovskiy, Daniil
    Thomas, Luc
    de la Cruz-Merino, Luis
    Dutriaux, Caroline
    Garbe, Claus
    Bartley, Karen
    Karagiannis, Thomas
    Chang, Ilsung
    Rooney, Isabelle
    Koralek, Daniel O.
    Larkin, James
    McArthur, Grant A.
    Ribas, Antoni
    [J]. BRITISH JOURNAL OF CANCER, 2018, 118 (06) : 777 - 784
  • [17] Phase 1b study of cobimetinib plus atezolizumab in patients with advanced BRAFV600 wild-type melanoma progressing on prior anti-programmed death-1 therapy
    Sandhu, Shahneen
    Atkinson, Victoria
    Cao, Maria Gonzalez
    Medina, Theresa
    Rivas, Ainara Soria
    Menzies, Alexander M.
    Caro, Ivor
    Roberts, Louise
    Song, Yuyao
    Yan, Yibing
    Guo, Yu
    Xue, Cloris
    Long, Georgina V.
    [J]. EUROPEAN JOURNAL OF CANCER, 2023, 178 : 180 - 190
  • [18] Prognostic subgroups and impact of treatment for post-progression overall survival (ppOS) in patients (pts) with BRAFV600-mutated metastatic melanoma treated with dacarbazine (DTIC) or vemurafenib (VEM) ± cobimetinib (COBI): A pooled analysis
    Ascierto, P. A.
    Ribas, A.
    Larkin, J.
    McArthur, G. A.
    Lewis, K. D.
    Hauschild, A.
    Flaherty, K. T.
    McKenna, E.
    Zhu, Q.
    Mun, Y.
    Dreno, B.
    [J]. ANNALS OF ONCOLOGY, 2016, 27
  • [19] Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF-mutated melanoma and other advanced malignancies
    Bhatty, Minny
    Kato, Shumei
    Piha-Paul, Sarina A.
    Naing, Aung
    Subbiah, Vivek
    Huang, Helen J.
    Karp, Daniel D.
    Tsimberidou, Apostolia M.
    Zinner, Ralph G.
    Hwu, Wen-Jen
    Javle, Milind
    Patel, Sapna P.
    Hu, Mimi, I
    Varadhachary, Gauri R.
    Conley, Anthony P.
    Ramzanali, Nishma M.
    Holley, Veronica R.
    Kurzrock, Razelle
    Meric-Bernstam, Funda
    Chae, Young Kwang
    Kim, Kevin B.
    Falchook, Gerald S.
    Janku, Filip
    [J]. CANCER, 2019, 125 (03) : 463 - 472
  • [20] Phase 1B study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated advanced cancers and metastatic colorectal cancer.
    Hong, David S.
    Morris, Van Karlyle
    Fu, Siqing
    Overman, Michael J.
    Piha-Paul, Sarina Anne
    Kee, Bryan K.
    Zinner, Ralph
    Fogelman, David R.
    Mistry, Reena
    Shureiqi, Imad
    Meric-Bernstam, Funda
    Kopetz, Scott
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345